nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—UGT1A4—Tamoxifen—pancreatic cancer	0.335	0.629	CbGbCtD
Asenapine—CYP1A2—Dacarbazine—pancreatic cancer	0.0315	0.0591	CbGbCtD
Asenapine—CYP1A2—Tamoxifen—pancreatic cancer	0.025	0.047	CbGbCtD
Asenapine—CYP1A2—Erlotinib—pancreatic cancer	0.0213	0.04	CbGbCtD
Asenapine—HRH2—gastric juice—pancreatic cancer	0.0209	0.427	CbGeAlD
Asenapine—CYP2D6—Tamoxifen—pancreatic cancer	0.0206	0.0388	CbGbCtD
Asenapine—CYP1A2—Fluorouracil—pancreatic cancer	0.0185	0.0347	CbGbCtD
Asenapine—CYP2D6—Erlotinib—pancreatic cancer	0.0175	0.033	CbGbCtD
Asenapine—CYP3A4—Tamoxifen—pancreatic cancer	0.0131	0.0246	CbGbCtD
Asenapine—HTR7—enteric nervous system—pancreatic cancer	0.0113	0.231	CbGeAlD
Asenapine—CYP3A4—Erlotinib—pancreatic cancer	0.0112	0.021	CbGbCtD
Asenapine—CYP3A4—Irinotecan—pancreatic cancer	0.0101	0.0189	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—pancreatic cancer	0.00865	0.0163	CbGbCtD
Asenapine—CYP3A4—Docetaxel—pancreatic cancer	0.00738	0.0139	CbGbCtD
Asenapine—CYP3A4—Sunitinib—pancreatic cancer	0.00735	0.0138	CbGbCtD
Asenapine—HTR2A—enteric nervous system—pancreatic cancer	0.00704	0.144	CbGeAlD
Asenapine—CYP3A4—Doxorubicin—pancreatic cancer	0.0055	0.0103	CbGbCtD
Asenapine—UGT1A4—digestive system—pancreatic cancer	0.00203	0.0416	CbGeAlD
Asenapine—HRH2—digestive system—pancreatic cancer	0.00127	0.0261	CbGeAlD
Asenapine—ADRA2A—islet of Langerhans—pancreatic cancer	0.000791	0.0162	CbGeAlD
Asenapine—SLC6A4—digestive system—pancreatic cancer	0.000763	0.0156	CbGeAlD
Asenapine—HTR2B—digestive system—pancreatic cancer	0.000756	0.0155	CbGeAlD
Asenapine—ADRA2C—pancreas—pancreatic cancer	0.000697	0.0143	CbGeAlD
Asenapine—HTR7—digestive system—pancreatic cancer	0.000647	0.0133	CbGeAlD
Asenapine—ADRA2A—pancreas—pancreatic cancer	0.000556	0.0114	CbGeAlD
Asenapine—CYP1A2—digestive system—pancreatic cancer	0.000516	0.0106	CbGeAlD
Asenapine—HRH1—digestive system—pancreatic cancer	0.000483	0.00989	CbGeAlD
Asenapine—HTR2A—digestive system—pancreatic cancer	0.000404	0.00826	CbGeAlD
Asenapine—CYP3A4—digestive system—pancreatic cancer	0.000374	0.00765	CbGeAlD
Asenapine—CYP2D6—digestive system—pancreatic cancer	0.000368	0.00753	CbGeAlD
Asenapine—Stomatitis—Docetaxel—pancreatic cancer	0.000345	0.00174	CcSEcCtD
Asenapine—Leukopenia—Fluorouracil—pancreatic cancer	0.000343	0.00173	CcSEcCtD
Asenapine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000342	0.00173	CcSEcCtD
Asenapine—Fatigue—Sunitinib—pancreatic cancer	0.000342	0.00173	CcSEcCtD
Asenapine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000341	0.00172	CcSEcCtD
Asenapine—Constipation—Sunitinib—pancreatic cancer	0.000339	0.00171	CcSEcCtD
Asenapine—Hypertension—Gemcitabine—pancreatic cancer	0.000336	0.0017	CcSEcCtD
Asenapine—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.000335	0.00169	CcSEcCtD
Asenapine—Asthenia—Tamoxifen—pancreatic cancer	0.000332	0.00168	CcSEcCtD
Asenapine—Convulsion—Fluorouracil—pancreatic cancer	0.000332	0.00168	CcSEcCtD
Asenapine—Arthralgia—Gemcitabine—pancreatic cancer	0.000332	0.00168	CcSEcCtD
Asenapine—Agranulocytosis—Docetaxel—pancreatic cancer	0.00033	0.00167	CcSEcCtD
Asenapine—Increased appetite—Epirubicin—pancreatic cancer	0.00033	0.00167	CcSEcCtD
Asenapine—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.000329	0.00166	CcSEcCtD
Asenapine—Asthenia—Erlotinib—pancreatic cancer	0.000328	0.00166	CcSEcCtD
Asenapine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000326	0.00165	CcSEcCtD
Asenapine—Dermatitis bullous—Epirubicin—pancreatic cancer	0.000324	0.00164	CcSEcCtD
Asenapine—Shock—Irinotecan—pancreatic cancer	0.000321	0.00162	CcSEcCtD
Asenapine—Nervous system disorder—Irinotecan—pancreatic cancer	0.00032	0.00162	CcSEcCtD
Asenapine—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.00032	0.00162	CcSEcCtD
Asenapine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00032	0.00162	CcSEcCtD
Asenapine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000318	0.00161	CcSEcCtD
Asenapine—Oedema peripheral—Docetaxel—pancreatic cancer	0.000313	0.00158	CcSEcCtD
Asenapine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000313	0.00158	CcSEcCtD
Asenapine—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000312	0.00158	CcSEcCtD
Asenapine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000312	0.00158	CcSEcCtD
Asenapine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000311	0.00157	CcSEcCtD
Asenapine—Hyponatraemia—Epirubicin—pancreatic cancer	0.000311	0.00157	CcSEcCtD
Asenapine—Pain in extremity—Epirubicin—pancreatic cancer	0.00031	0.00156	CcSEcCtD
Asenapine—Osteoarthritis—Epirubicin—pancreatic cancer	0.00031	0.00156	CcSEcCtD
Asenapine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000307	0.00155	CcSEcCtD
Asenapine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000306	0.00155	CcSEcCtD
Asenapine—Dizziness—Tamoxifen—pancreatic cancer	0.000306	0.00155	CcSEcCtD
Asenapine—Tachycardia—Fluorouracil—pancreatic cancer	0.000305	0.00154	CcSEcCtD
Asenapine—Hypotension—Irinotecan—pancreatic cancer	0.000305	0.00154	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—pancreatic cancer	0.000305	0.00154	CcSEcCtD
Asenapine—Dizziness—Erlotinib—pancreatic cancer	0.000303	0.00153	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—pancreatic cancer	0.0003	0.00151	CcSEcCtD
Asenapine—Hypotension—Gemcitabine—pancreatic cancer	0.000297	0.0015	CcSEcCtD
Asenapine—Eye disorder—Docetaxel—pancreatic cancer	0.000297	0.0015	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000296	0.0015	CcSEcCtD
Asenapine—Insomnia—Irinotecan—pancreatic cancer	0.000295	0.00149	CcSEcCtD
Asenapine—Cardiac disorder—Docetaxel—pancreatic cancer	0.000295	0.00149	CcSEcCtD
Asenapine—Vomiting—Tamoxifen—pancreatic cancer	0.000294	0.00149	CcSEcCtD
Asenapine—Hypotension—Fluorouracil—pancreatic cancer	0.000292	0.00148	CcSEcCtD
Asenapine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000292	0.00148	CcSEcCtD
Asenapine—Rash—Tamoxifen—pancreatic cancer	0.000292	0.00147	CcSEcCtD
Asenapine—Dermatitis—Tamoxifen—pancreatic cancer	0.000291	0.00147	CcSEcCtD
Asenapine—Vomiting—Erlotinib—pancreatic cancer	0.000291	0.00147	CcSEcCtD
Asenapine—Dyspnoea—Irinotecan—pancreatic cancer	0.000291	0.00147	CcSEcCtD
Asenapine—Somnolence—Irinotecan—pancreatic cancer	0.00029	0.00147	CcSEcCtD
Asenapine—Headache—Tamoxifen—pancreatic cancer	0.00029	0.00146	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00029	0.00146	CcSEcCtD
Asenapine—Rash—Erlotinib—pancreatic cancer	0.000289	0.00146	CcSEcCtD
Asenapine—Dermatitis—Erlotinib—pancreatic cancer	0.000288	0.00146	CcSEcCtD
Asenapine—Angiopathy—Docetaxel—pancreatic cancer	0.000288	0.00146	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—pancreatic cancer	0.000288	0.00145	CcSEcCtD
Asenapine—Insomnia—Gemcitabine—pancreatic cancer	0.000288	0.00145	CcSEcCtD
Asenapine—Dyspepsia—Irinotecan—pancreatic cancer	0.000287	0.00145	CcSEcCtD
Asenapine—Immune system disorder—Docetaxel—pancreatic cancer	0.000287	0.00145	CcSEcCtD
Asenapine—Headache—Erlotinib—pancreatic cancer	0.000287	0.00145	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—pancreatic cancer	0.000286	0.00145	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000286	0.00145	CcSEcCtD
Asenapine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000286	0.00145	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000285	0.00144	CcSEcCtD
Asenapine—Asthenia—Sunitinib—pancreatic cancer	0.000284	0.00144	CcSEcCtD
Asenapine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000283	0.00143	CcSEcCtD
Asenapine—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000283	0.00143	CcSEcCtD
Asenapine—Insomnia—Fluorouracil—pancreatic cancer	0.000283	0.00143	CcSEcCtD
Asenapine—Somnolence—Gemcitabine—pancreatic cancer	0.000283	0.00143	CcSEcCtD
Asenapine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000282	0.00142	CcSEcCtD
Asenapine—Fatigue—Irinotecan—pancreatic cancer	0.000281	0.00142	CcSEcCtD
Asenapine—Breast disorder—Epirubicin—pancreatic cancer	0.00028	0.00141	CcSEcCtD
Asenapine—Constipation—Irinotecan—pancreatic cancer	0.000279	0.00141	CcSEcCtD
Asenapine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000279	0.00141	CcSEcCtD
Asenapine—Mental disorder—Docetaxel—pancreatic cancer	0.000278	0.00141	CcSEcCtD
Asenapine—Somnolence—Fluorouracil—pancreatic cancer	0.000278	0.0014	CcSEcCtD
Asenapine—Malnutrition—Docetaxel—pancreatic cancer	0.000276	0.0014	CcSEcCtD
Asenapine—Dyspepsia—Fluorouracil—pancreatic cancer	0.000275	0.00139	CcSEcCtD
Asenapine—Nausea—Tamoxifen—pancreatic cancer	0.000275	0.00139	CcSEcCtD
Asenapine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000274	0.00139	CcSEcCtD
Asenapine—Fatigue—Gemcitabine—pancreatic cancer	0.000274	0.00139	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000273	0.00138	CcSEcCtD
Asenapine—Constipation—Gemcitabine—pancreatic cancer	0.000272	0.00137	CcSEcCtD
Asenapine—Nausea—Erlotinib—pancreatic cancer	0.000272	0.00137	CcSEcCtD
Asenapine—Dysgeusia—Docetaxel—pancreatic cancer	0.000271	0.00137	CcSEcCtD
Asenapine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00027	0.00136	CcSEcCtD
Asenapine—Dysphagia—Epirubicin—pancreatic cancer	0.000268	0.00135	CcSEcCtD
Asenapine—Muscle spasms—Docetaxel—pancreatic cancer	0.000266	0.00134	CcSEcCtD
Asenapine—Dizziness—Sunitinib—pancreatic cancer	0.000262	0.00132	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000262	0.00132	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—pancreatic cancer	0.000259	0.00131	CcSEcCtD
Asenapine—Anaemia—Docetaxel—pancreatic cancer	0.000256	0.00129	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000253	0.00128	CcSEcCtD
Asenapine—Vomiting—Sunitinib—pancreatic cancer	0.000252	0.00127	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—pancreatic cancer	0.00025	0.00126	CcSEcCtD
Asenapine—Rash—Sunitinib—pancreatic cancer	0.00025	0.00126	CcSEcCtD
Asenapine—Dermatitis—Sunitinib—pancreatic cancer	0.00025	0.00126	CcSEcCtD
Asenapine—Headache—Sunitinib—pancreatic cancer	0.000248	0.00125	CcSEcCtD
Asenapine—Syncope—Docetaxel—pancreatic cancer	0.000248	0.00125	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—pancreatic cancer	0.000248	0.00125	CcSEcCtD
Asenapine—Leukopenia—Docetaxel—pancreatic cancer	0.000247	0.00125	CcSEcCtD
Asenapine—Weight increased—Epirubicin—pancreatic cancer	0.000244	0.00123	CcSEcCtD
Asenapine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000243	0.00123	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000241	0.00122	CcSEcCtD
Asenapine—Hypersensitivity—Irinotecan—pancreatic cancer	0.00024	0.00122	CcSEcCtD
Asenapine—Convulsion—Docetaxel—pancreatic cancer	0.00024	0.00121	CcSEcCtD
Asenapine—Hypertension—Docetaxel—pancreatic cancer	0.000239	0.00121	CcSEcCtD
Asenapine—Arthralgia—Docetaxel—pancreatic cancer	0.000235	0.00119	CcSEcCtD
Asenapine—Nausea—Sunitinib—pancreatic cancer	0.000235	0.00119	CcSEcCtD
Asenapine—Asthenia—Irinotecan—pancreatic cancer	0.000234	0.00118	CcSEcCtD
Asenapine—Stomatitis—Epirubicin—pancreatic cancer	0.000233	0.00118	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—pancreatic cancer	0.000232	0.00117	CcSEcCtD
Asenapine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00023	0.00116	CcSEcCtD
Asenapine—Dry mouth—Docetaxel—pancreatic cancer	0.00023	0.00116	CcSEcCtD
Asenapine—Asthenia—Gemcitabine—pancreatic cancer	0.000228	0.00115	CcSEcCtD
Asenapine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000226	0.00114	CcSEcCtD
Asenapine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000226	0.00114	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—pancreatic cancer	0.000225	0.00114	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000223	0.00113	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—pancreatic cancer	0.000223	0.00113	CcSEcCtD
Asenapine—Shock—Docetaxel—pancreatic cancer	0.000222	0.00112	CcSEcCtD
Asenapine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000221	0.00112	CcSEcCtD
Asenapine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000221	0.00112	CcSEcCtD
Asenapine—Tachycardia—Docetaxel—pancreatic cancer	0.00022	0.00111	CcSEcCtD
Asenapine—Dizziness—Irinotecan—pancreatic cancer	0.000216	0.00109	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—pancreatic cancer	0.000215	0.00109	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000211	0.00107	CcSEcCtD
Asenapine—Hypotension—Docetaxel—pancreatic cancer	0.000211	0.00107	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.00021	0.00106	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000209	0.00106	CcSEcCtD
Asenapine—Vomiting—Irinotecan—pancreatic cancer	0.000208	0.00105	CcSEcCtD
Asenapine—Dizziness—Fluorouracil—pancreatic cancer	0.000207	0.00104	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000206	0.00104	CcSEcCtD
Asenapine—Rash—Irinotecan—pancreatic cancer	0.000206	0.00104	CcSEcCtD
Asenapine—Dermatitis—Irinotecan—pancreatic cancer	0.000206	0.00104	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000206	0.00104	CcSEcCtD
Asenapine—Headache—Irinotecan—pancreatic cancer	0.000204	0.00103	CcSEcCtD
Asenapine—Insomnia—Docetaxel—pancreatic cancer	0.000204	0.00103	CcSEcCtD
Asenapine—Vomiting—Gemcitabine—pancreatic cancer	0.000202	0.00102	CcSEcCtD
Asenapine—Dyspnoea—Docetaxel—pancreatic cancer	0.000201	0.00102	CcSEcCtD
Asenapine—Somnolence—Docetaxel—pancreatic cancer	0.000201	0.00101	CcSEcCtD
Asenapine—Rash—Gemcitabine—pancreatic cancer	0.0002	0.00101	CcSEcCtD
Asenapine—Dermatitis—Gemcitabine—pancreatic cancer	0.0002	0.00101	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—pancreatic cancer	0.0002	0.00101	CcSEcCtD
Asenapine—Headache—Gemcitabine—pancreatic cancer	0.000199	0.00101	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—pancreatic cancer	0.000199	0.001	CcSEcCtD
Asenapine—Vomiting—Fluorouracil—pancreatic cancer	0.000199	0.001	CcSEcCtD
Asenapine—Dyspepsia—Docetaxel—pancreatic cancer	0.000199	0.001	CcSEcCtD
Asenapine—Rash—Fluorouracil—pancreatic cancer	0.000197	0.000996	CcSEcCtD
Asenapine—Dermatitis—Fluorouracil—pancreatic cancer	0.000197	0.000995	CcSEcCtD
Asenapine—Headache—Fluorouracil—pancreatic cancer	0.000196	0.00099	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000195	0.000987	CcSEcCtD
Asenapine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000195	0.000984	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000195	0.000984	CcSEcCtD
Asenapine—Fatigue—Docetaxel—pancreatic cancer	0.000195	0.000983	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—pancreatic cancer	0.000194	0.000982	CcSEcCtD
Asenapine—Nausea—Irinotecan—pancreatic cancer	0.000194	0.00098	CcSEcCtD
Asenapine—Immune system disorder—Epirubicin—pancreatic cancer	0.000193	0.000978	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000193	0.000976	CcSEcCtD
Asenapine—Constipation—Docetaxel—pancreatic cancer	0.000193	0.000975	CcSEcCtD
Asenapine—Nausea—Gemcitabine—pancreatic cancer	0.000189	0.000954	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—pancreatic cancer	0.000188	0.000948	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—pancreatic cancer	0.000186	0.000942	CcSEcCtD
Asenapine—Nausea—Fluorouracil—pancreatic cancer	0.000186	0.000938	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—pancreatic cancer	0.000185	0.000936	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000184	0.00093	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—pancreatic cancer	0.000183	0.000923	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—pancreatic cancer	0.00018	0.000909	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—pancreatic cancer	0.000179	0.000906	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—pancreatic cancer	0.000179	0.000905	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000179	0.000903	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—pancreatic cancer	0.000174	0.000878	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—pancreatic cancer	0.000173	0.000872	CcSEcCtD
Asenapine—Anaemia—Epirubicin—pancreatic cancer	0.000172	0.000871	CcSEcCtD
Asenapine—Agitation—Epirubicin—pancreatic cancer	0.000171	0.000866	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—pancreatic cancer	0.000169	0.000854	CcSEcCtD
Asenapine—Malaise—Epirubicin—pancreatic cancer	0.000168	0.00085	CcSEcCtD
Asenapine—Syncope—Epirubicin—pancreatic cancer	0.000167	0.000845	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—pancreatic cancer	0.000167	0.000844	CcSEcCtD
Asenapine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000166	0.00084	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000166	0.000838	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000164	0.000828	CcSEcCtD
Asenapine—Asthenia—Docetaxel—pancreatic cancer	0.000162	0.000818	CcSEcCtD
Asenapine—Convulsion—Epirubicin—pancreatic cancer	0.000162	0.000816	CcSEcCtD
Asenapine—Hypertension—Epirubicin—pancreatic cancer	0.000161	0.000814	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—pancreatic cancer	0.000159	0.000806	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—pancreatic cancer	0.000159	0.000802	CcSEcCtD
Asenapine—Agitation—Doxorubicin—pancreatic cancer	0.000159	0.000801	CcSEcCtD
Asenapine—Anxiety—Epirubicin—pancreatic cancer	0.000158	0.0008	CcSEcCtD
Asenapine—Malaise—Doxorubicin—pancreatic cancer	0.000156	0.000786	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—pancreatic cancer	0.000155	0.000785	CcSEcCtD
Asenapine—Syncope—Doxorubicin—pancreatic cancer	0.000155	0.000782	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—pancreatic cancer	0.000154	0.000781	CcSEcCtD
Asenapine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000152	0.000769	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000152	0.000766	CcSEcCtD
Asenapine—Shock—Epirubicin—pancreatic cancer	0.00015	0.000757	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—pancreatic cancer	0.000149	0.000755	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000149	0.000754	CcSEcCtD
Asenapine—Dizziness—Docetaxel—pancreatic cancer	0.000149	0.000754	CcSEcCtD
Asenapine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000149	0.000753	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—pancreatic cancer	0.000149	0.000753	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—pancreatic cancer	0.000149	0.000751	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—pancreatic cancer	0.000147	0.000742	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—pancreatic cancer	0.000146	0.00074	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—pancreatic cancer	0.000144	0.000726	CcSEcCtD
Asenapine—Vomiting—Docetaxel—pancreatic cancer	0.000143	0.000725	CcSEcCtD
Asenapine—Rash—Docetaxel—pancreatic cancer	0.000142	0.000719	CcSEcCtD
Asenapine—Hypotension—Epirubicin—pancreatic cancer	0.000142	0.000719	CcSEcCtD
Asenapine—Dermatitis—Docetaxel—pancreatic cancer	0.000142	0.000718	CcSEcCtD
Asenapine—Headache—Docetaxel—pancreatic cancer	0.000141	0.000714	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000141	0.000712	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000139	0.000701	CcSEcCtD
Asenapine—Shock—Doxorubicin—pancreatic cancer	0.000139	0.0007	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000138	0.000698	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000138	0.000697	CcSEcCtD
Asenapine—Insomnia—Epirubicin—pancreatic cancer	0.000138	0.000696	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—pancreatic cancer	0.000137	0.000695	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—pancreatic cancer	0.000136	0.000686	CcSEcCtD
Asenapine—Somnolence—Epirubicin—pancreatic cancer	0.000135	0.000684	CcSEcCtD
Asenapine—Nausea—Docetaxel—pancreatic cancer	0.000134	0.000677	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—pancreatic cancer	0.000134	0.000677	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—pancreatic cancer	0.000132	0.000665	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000131	0.000664	CcSEcCtD
Asenapine—Fatigue—Epirubicin—pancreatic cancer	0.000131	0.000663	CcSEcCtD
Asenapine—Constipation—Epirubicin—pancreatic cancer	0.00013	0.000658	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000128	0.000648	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—pancreatic cancer	0.000127	0.000644	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000126	0.000634	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—pancreatic cancer	0.000125	0.000633	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000124	0.000626	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000122	0.000614	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—pancreatic cancer	0.000121	0.000614	CcSEcCtD
Asenapine—Constipation—Doxorubicin—pancreatic cancer	0.00012	0.000609	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000112	0.000567	CcSEcCtD
Asenapine—Asthenia—Epirubicin—pancreatic cancer	0.000109	0.000552	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000104	0.000524	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—pancreatic cancer	0.000101	0.000511	CcSEcCtD
Asenapine—Dizziness—Epirubicin—pancreatic cancer	0.000101	0.000509	CcSEcCtD
Asenapine—Vomiting—Epirubicin—pancreatic cancer	9.68e-05	0.000489	CcSEcCtD
Asenapine—Rash—Epirubicin—pancreatic cancer	9.6e-05	0.000485	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—pancreatic cancer	9.59e-05	0.000484	CcSEcCtD
Asenapine—Headache—Epirubicin—pancreatic cancer	9.53e-05	0.000482	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—pancreatic cancer	9.31e-05	0.000471	CcSEcCtD
Asenapine—Nausea—Epirubicin—pancreatic cancer	9.04e-05	0.000457	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—pancreatic cancer	8.95e-05	0.000452	CcSEcCtD
Asenapine—Rash—Doxorubicin—pancreatic cancer	8.88e-05	0.000449	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—pancreatic cancer	8.87e-05	0.000448	CcSEcCtD
Asenapine—Headache—Doxorubicin—pancreatic cancer	8.82e-05	0.000446	CcSEcCtD
Asenapine—Nausea—Doxorubicin—pancreatic cancer	8.36e-05	0.000423	CcSEcCtD
Asenapine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	4.71e-06	2.13e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	4.71e-06	2.13e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	4.7e-06	2.13e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—STK11—pancreatic cancer	4.7e-06	2.13e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	4.68e-06	2.12e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—MYC—pancreatic cancer	4.68e-06	2.12e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	4.68e-06	2.12e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	4.67e-06	2.12e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	4.67e-06	2.11e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	4.67e-06	2.11e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—SRC—pancreatic cancer	4.65e-06	2.11e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	4.65e-06	2.1e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	4.64e-06	2.1e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—EGFR—pancreatic cancer	4.64e-06	2.1e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	4.63e-06	2.1e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	4.63e-06	2.1e-05	CbGpPWpGaD
Asenapine—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	4.63e-06	2.09e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	4.62e-06	2.09e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTEN—pancreatic cancer	4.61e-06	2.09e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.61e-06	2.08e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	4.59e-06	2.08e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	4.59e-06	2.08e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	4.59e-06	2.08e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CASP3—pancreatic cancer	4.59e-06	2.08e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	4.58e-06	2.07e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—EGFR—pancreatic cancer	4.58e-06	2.07e-05	CbGpPWpGaD
Asenapine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.55e-06	2.06e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—SRC—pancreatic cancer	4.55e-06	2.06e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	4.55e-06	2.06e-05	CbGpPWpGaD
Asenapine—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	4.54e-06	2.06e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	4.54e-06	2.06e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.54e-06	2.05e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	4.54e-06	2.05e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	4.53e-06	2.05e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	4.53e-06	2.05e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—pancreatic cancer	4.52e-06	2.05e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—pancreatic cancer	4.52e-06	2.05e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	4.51e-06	2.04e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CASP3—pancreatic cancer	4.5e-06	2.04e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—pancreatic cancer	4.49e-06	2.03e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	4.49e-06	2.03e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	4.48e-06	2.03e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	4.47e-06	2.02e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—pancreatic cancer	4.46e-06	2.02e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	4.46e-06	2.02e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	4.46e-06	2.02e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	4.43e-06	2.01e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	4.42e-06	2e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	4.42e-06	2e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	4.41e-06	2e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	4.4e-06	1.99e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—pancreatic cancer	4.4e-06	1.99e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	4.39e-06	1.99e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	4.39e-06	1.99e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—pancreatic cancer	4.38e-06	1.98e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—pancreatic cancer	4.38e-06	1.98e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.38e-06	1.98e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	4.38e-06	1.98e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	4.37e-06	1.98e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	4.36e-06	1.97e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	4.35e-06	1.97e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	4.34e-06	1.96e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MMP9—pancreatic cancer	4.33e-06	1.96e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	4.33e-06	1.96e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—pancreatic cancer	4.33e-06	1.96e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—pancreatic cancer	4.32e-06	1.96e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—pancreatic cancer	4.32e-06	1.96e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—pancreatic cancer	4.31e-06	1.95e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	4.3e-06	1.95e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	4.29e-06	1.94e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	4.29e-06	1.94e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	4.29e-06	1.94e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.27e-06	1.93e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	4.26e-06	1.93e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—pancreatic cancer	4.26e-06	1.93e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	4.26e-06	1.93e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—APOE—pancreatic cancer	4.26e-06	1.93e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	4.26e-06	1.93e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MMP9—pancreatic cancer	4.26e-06	1.93e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	4.25e-06	1.92e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	4.25e-06	1.92e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	4.24e-06	1.92e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	4.24e-06	1.92e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—pancreatic cancer	4.23e-06	1.91e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	4.22e-06	1.91e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	4.21e-06	1.91e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	4.2e-06	1.9e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	4.2e-06	1.9e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	4.18e-06	1.89e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—pancreatic cancer	4.17e-06	1.89e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	4.17e-06	1.89e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	4.16e-06	1.88e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	4.15e-06	1.88e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.14e-06	1.88e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—pancreatic cancer	4.14e-06	1.87e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	4.14e-06	1.87e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	4.13e-06	1.87e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—pancreatic cancer	4.13e-06	1.87e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	4.13e-06	1.87e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	4.11e-06	1.86e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	4.08e-06	1.85e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—pancreatic cancer	4.08e-06	1.85e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	4.07e-06	1.84e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	4.06e-06	1.84e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	4.05e-06	1.83e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	4.05e-06	1.83e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.04e-06	1.83e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.03e-06	1.83e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	4.03e-06	1.82e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	4.01e-06	1.81e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	4e-06	1.81e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—SRC—pancreatic cancer	4e-06	1.81e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.99e-06	1.81e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	3.99e-06	1.81e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	3.97e-06	1.8e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	3.97e-06	1.8e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	3.96e-06	1.79e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	3.95e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	3.95e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	3.94e-06	1.78e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	3.94e-06	1.78e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	3.93e-06	1.78e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—SRC—pancreatic cancer	3.92e-06	1.78e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	3.9e-06	1.77e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—pancreatic cancer	3.89e-06	1.76e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	3.89e-06	1.76e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	3.88e-06	1.76e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	3.86e-06	1.75e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	3.86e-06	1.75e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	3.85e-06	1.74e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STAT3—pancreatic cancer	3.85e-06	1.74e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	3.85e-06	1.74e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.85e-06	1.74e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—pancreatic cancer	3.84e-06	1.74e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—pancreatic cancer	3.84e-06	1.74e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	3.83e-06	1.73e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	3.82e-06	1.73e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	3.82e-06	1.73e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—pancreatic cancer	3.82e-06	1.73e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	3.79e-06	1.72e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	3.79e-06	1.72e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STAT3—pancreatic cancer	3.78e-06	1.71e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	3.78e-06	1.71e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—pancreatic cancer	3.77e-06	1.71e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	3.77e-06	1.71e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	3.76e-06	1.7e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	3.75e-06	1.7e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	3.75e-06	1.7e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—pancreatic cancer	3.72e-06	1.69e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	3.71e-06	1.68e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	3.71e-06	1.68e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.71e-06	1.68e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	3.7e-06	1.68e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—pancreatic cancer	3.68e-06	1.66e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—pancreatic cancer	3.65e-06	1.65e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	3.65e-06	1.65e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	3.62e-06	1.64e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	3.59e-06	1.62e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—pancreatic cancer	3.58e-06	1.62e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	3.58e-06	1.62e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	3.57e-06	1.62e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	3.54e-06	1.6e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	3.52e-06	1.59e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—pancreatic cancer	3.52e-06	1.59e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	3.51e-06	1.59e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	3.51e-06	1.59e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—pancreatic cancer	3.5e-06	1.59e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—pancreatic cancer	3.5e-06	1.58e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	3.49e-06	1.58e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	3.48e-06	1.58e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.48e-06	1.57e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	3.47e-06	1.57e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.46e-06	1.57e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	3.45e-06	1.56e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	3.45e-06	1.56e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.45e-06	1.56e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	3.45e-06	1.56e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.44e-06	1.56e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	3.44e-06	1.56e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	3.44e-06	1.56e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—pancreatic cancer	3.44e-06	1.56e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—pancreatic cancer	3.43e-06	1.55e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.38e-06	1.53e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	3.37e-06	1.53e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.35e-06	1.52e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—pancreatic cancer	3.35e-06	1.52e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	3.35e-06	1.52e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	3.33e-06	1.51e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	3.32e-06	1.5e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—pancreatic cancer	3.31e-06	1.5e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—pancreatic cancer	3.29e-06	1.49e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—APOE—pancreatic cancer	3.29e-06	1.49e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	3.28e-06	1.48e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—pancreatic cancer	3.27e-06	1.48e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	3.26e-06	1.47e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	3.25e-06	1.47e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—pancreatic cancer	3.25e-06	1.47e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—pancreatic cancer	3.24e-06	1.47e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	3.24e-06	1.47e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	3.21e-06	1.45e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	3.2e-06	1.45e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	3.2e-06	1.45e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	3.19e-06	1.44e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.19e-06	1.44e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	3.13e-06	1.42e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	3.1e-06	1.4e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	3.04e-06	1.38e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.01e-06	1.36e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.99e-06	1.35e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	2.98e-06	1.35e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.97e-06	1.34e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.96e-06	1.34e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	2.96e-06	1.34e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.95e-06	1.33e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—pancreatic cancer	2.94e-06	1.33e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	2.93e-06	1.33e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.93e-06	1.33e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.92e-06	1.32e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	2.89e-06	1.31e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	2.89e-06	1.31e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—pancreatic cancer	2.89e-06	1.31e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.86e-06	1.3e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	2.83e-06	1.28e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	2.83e-06	1.28e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	2.81e-06	1.27e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—pancreatic cancer	2.81e-06	1.27e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	2.77e-06	1.25e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—pancreatic cancer	2.76e-06	1.25e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	2.74e-06	1.24e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.72e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	2.71e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.66e-06	1.2e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	2.63e-06	1.19e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.61e-06	1.18e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.55e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	2.52e-06	1.14e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—pancreatic cancer	2.48e-06	1.12e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	2.44e-06	1.11e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—pancreatic cancer	2.44e-06	1.1e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	2.39e-06	1.08e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.27e-06	1.03e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.25e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.22e-06	1.01e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.12e-06	9.6e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.97e-06	8.89e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.8e-06	8.13e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.73e-06	7.84e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.47e-06	6.64e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.39e-06	6.27e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.13e-06	5.13e-06	CbGpPWpGaD
